ALLO (Allogene Therapeutics) Marketable Securities: $236.58 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALLO Allogene Therapeutics Inc ALLO
32 GF Score
Price $2.07
! 3 Warning Signs
View Full Analysis

What is Allogene Therapeutics Marketable Securities?

Allogene Therapeutics ALLO +2.99% 32 Marketable Securities is $236.58 Mil as of Mar. 2026. GuruFocus rates ALLO with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Allogene Therapeutics's Marketable Securities for the quarter that ended in Mar. 2026 was $236.58 Mil.

Allogene Therapeutics's annual Marketable Securities declined from Dec. 2023 ($365.54 Mil) to Dec. 2024 ($217.26 Mil) and declined from Dec. 2024 ($217.26 Mil) to Dec. 2025 ($198.52 Mil).

Allogene Therapeutics  (NAS:ALLO) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Allogene Therapeutics Marketable Securities Related Terms

Allogene Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Allogene Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allogene Therapeutics Marketable Securities Chart

Allogene Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only 283.99 455.42 365.54 217.26 198.52

Allogene Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 237.59 220.79 214.38 198.52 236.58
ALLO
32GF Score
Allogene Therapeutics Inc ALLO
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Allogene Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $236.58 Mil mean?
Allogene Therapeutics (ALLO) has a Marketable Securities of $236.58 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Allogene Therapeutics and its competitors.
Is Allogene Therapeutics' Marketable Securities too high?
Allogene Therapeutics' current Marketable Securities is $236.58 Mil. Overall, Allogene Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Allogene Therapeutics' Marketable Securities compare to CBIO and IMMX?
Allogene Therapeutics' Marketable Securities of $236.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Allogene Therapeutics and its competitors. Allogene Therapeutics's current Marketable Securities is $236.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allogene Therapeutics stock overvalued right now?
Allogene Therapeutics (ALLO) has a current Marketable Securities of $236.58 Mil. The current Marketable Securities is $236.58 Mil. Allogene Therapeutics' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Allogene Therapeutics (ALLO), the current Marketable Securities is $236.58 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allogene Therapeutics Business Description

Address 210 East Grand Avenue, South San Francisco, CA, USA, 94080
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
32GF Score

Get the complete analysis for ALLO

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.07
Price